Regular ArticleManagement of pregnant women with mechanical heart valve prosthesis: Thromboprophylaxis with Low molecular weight heparin
Introduction
Pregnancy increases the risk of mechanical heart valve thrombosis [1], [2] and effective anticoagulation is mandatory [3]. Oral anticoagulants (OA) offer the best protection against thrombosis, but their use is associated with an appreciable risk of fetal malformations and pregnancy loss [4]. Substituting OA with unfractionated heparin (UFH) reduces the risk of fetal damage, but increases the risk of valve thrombosis, even when administered in adjusted doses [4], [5].
A woman with mechanical heart valve prosthesis (MHV) contacted us in 1996 because she wished to become pregnant. She had suffered from abortions while on warfarin during her earlier pregnancies and she demanded an alternative thromboprophylaxis. Low molecular weight heparin (LMWH) has a longer duration and results in more predictable plasma concentrations compared to UFH [6]. We concluded that prophylaxis with therapeutic doses of LMWH under frequent blood monitoring and echocardiographic examination would be a logical alternative for our patient. Pregnancy and delivery were uneventful and the regimen was outlined in the Journal of the Norwegian Medical Association [7]. The regimen was used in 11 additional pregnancies monitored at five Norwegian centers.
The present retrospective case series includes all the 12 pregnancies in women with MHV treated with adjusted, therapeutic doses of LMWH in Norway during 1997-2008. In addition, we have performed a systematic literature search and calculated the pooled frequencies of thromboembolism associated with the different anticoagulation regimes in pregnant women with MHV.
Section snippets
Patients
In order to include all relevant pregnancies, the plan of the present report was described in an article in the May 2006 issue of the Newsletter of the Norwegian Society of Cardiology. The importance of including all women with MHV that had been treated with therapeutic doses of LMWH was emphasized, and physicians were requested to contact the first author. Because local registries did not identify all relevant pregnancies, cardiologists, cardiac surgeons, hematologists, and internists engaged
Outcomes
Symptoms suggesting thrombosis or bleeding were not observed during any of the ten pregnancies in which therapeutic doses of LMWH had been used already within the first week after cessation of warfarin (Table 2). Two women with aortic valve prosthesis (Table 2, no 5 and 6) were prescribed subtherapeutic LMWH (110 IU/kg/24 h once daily in combination with aspirin 75 mg once daily, and 55 IU/kg/24 h twice daily, respectively) by their caring physicians during the initial 20 and 27 days,
Discussion
Effective anticoagulation in pregnant women with MHV is imperative. In the lack of properly sized randomized clinical studies, systematic reviews are important tools for comparisons. Covering the literature prior to 1998, Chan et al reported pooled estimates on the risk of thromboembolic complications. In order to reduce selection bias, these authors included only reports that concerned 6 or more pregnancies [4]. They reported, that with no anticoagulation, thromboembolism occurred in 25.4% of
Limitations of the study
All reports on the effect of LMWH prophylaxis in women with MHV, including the present case series, contain few patients. Although considerable effort was taken to include all relevant pregnancies, we may have missed some. Even when pooling the results, the results with various anticoagulation regimes mostly consist of few patients, and the risk estimates calculated have large confidence intervals.
Conflicts of interest
None
Acknowledgements
The following physicians participated in the monitoring of the patients: Stefan Elvström, Alf Ihlen, Idunn Myklebust, Tone Nerdrum, Anne Mette Njaastad, Gunnar Rongved, and Sigurd Vatn.
References (39)
- et al.
Cardiac valve prostheses, anticoagulation, and pregnancy
Ann Thorac Surg
(1977) - et al.
Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses
J Am Coll Cardiol
(1996) - et al.
Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis
J Thromb Haemost
(2006) Confidence intervals for the odds ratio in case-control studies: the state of the art
J Chronic Dis
(1979)- et al.
Enoxaparin treatment in women with mechanical heart valves during pregnancy
Am J Obstet Gynecol
(2001) - et al.
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest
(2008) - et al.
Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves
J Am Coll Cardiol
(1999) - et al.
Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges
Thromb Res
(2002) - et al.
A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation
Am J Obstet Gynecol
(2004) - et al.
Pregnancy after mechanical mitral valve replacement
J Heart Valve Dis
(2003)